These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26387697)

  • 1. [Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer].
    Ryu JK
    Korean J Gastroenterol; 2015 Sep; 66(3):150-3. PubMed ID: 26387697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.
    Zhao J; Shen H; Hu HG; Huang JJ
    World J Gastroenterol; 2015 Mar; 21(11):3441-6. PubMed ID: 25805958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Boeck S; Heinemann V
    J Clin Oncol; 2008 Mar; 26(7):1178-9; author reply 1179. PubMed ID: 18309957
    [No Abstract]   [Full Text] [Related]  

  • 4. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
    Kourie HR; Gharios J; Kattan J
    Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286
    [No Abstract]   [Full Text] [Related]  

  • 5. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
    Saif MW
    JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of metastatic pancreatic cancer.
    Ko AH; Tempero MA
    J Natl Compr Canc Netw; 2005 Sep; 3(5):627-36. PubMed ID: 16194454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
    Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
    Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.
    Boeck S; Heinemann V
    Future Oncol; 2008 Feb; 4(1):41-50. PubMed ID: 18240999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
    Kozuch P; Petryk M; Evans A; Bruckner HW
    Surg Clin North Am; 2001 Jun; 81(3):683-90. PubMed ID: 11459281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemoradiation for pancreatic adenocarcinoma].
    Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
    Brunet R; Fonck M
    Rev Med Interne; 1999 Sep; 20(9):816-20. PubMed ID: 10522306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
    Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Rabbi C; Marangolo M
    J Chemother; 2004 Dec; 16(6):589-94. PubMed ID: 15700852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palliative chemotherapy for pancreatic malignancies.
    Mehta SP
    Surg Clin North Am; 2010 Apr; 90(2):365-75. PubMed ID: 20362792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional chemotherapy of advanced pancreatic cancer.
    Giuliani F; Di Maio M; Colucci G; Perrone F
    Curr Drug Targets; 2012 Jun; 13(6):795-801. PubMed ID: 22458526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical update of gemcitabine in pancreas cancer.
    Au E
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():469-73. PubMed ID: 10895197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial.
    Gansauge F; Ramadani M; Pressmar J; Gansauge S; Muehling B; Stecker K; Cammerer G; Leder G; Beger HG
    Langenbecks Arch Surg; 2002 Mar; 386(8):570-4. PubMed ID: 11914932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
    Kawashima H; Itoh A; Ohno E; Nakamura M; Miyahara R; Ohmiya N; Hara K; Kanamori A; Itoh T; Taki T; Hirai T; Hashimoto S; Takeda K; Goto H; Hirooka Y
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):677-83. PubMed ID: 21132496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.